Slim chance participants in phase 1 cancer trials will benefit

Only a tiny proportion of therapies are ultimately approved, researchers say

The chance that a therapy used on a patient in a phase 1 cancer trial will be later approved by the US Food and Drug Administration is almost as slim as one in a 100, a review suggests.